Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 6Neoplasms 5Small Cell Lung Carcinoma 3Neoplasm Metastasis 3Nasopharyngeal Carcinoma 2Esophageal Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Advanced Cancer 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Stereotactic Body Radiation Therapy 1Sarcoma 1Recurrence 1Platinum-resistant Recurrent Clear Cell Ovarian Cancer 1Pheochromocytoma 1Paraganglioma, Extra-Adrenal 1Paraganglioma 1Pancreatic Neoplasms 1NSCLC 1Lung Neoplasms 1Esophageal Squamous Cell Carcinoma 1Colonic Neoplasms 1Carcinoma, Medullary 1Brain Neoplasms 1Advanced Solid Tumors 1Advanced Malignancy 1Advanced Endometrial Cancer 1Adenocarcinoma of Lung 1

Interventions

vandetanib 9Everolimus 4Sorafenib 3sargramostim 2cabozantinib 2Trastuzumab 2Sunitinib 2Gefitinib 2Doxorubicin 2yeast-CEA vaccine 1vatalanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1temsirolimus 1tanespimycin 1sacubitril and valsartan sodium hydrate drug combination 1pralsetinib 1pembrolizumab 1pazopanib 1pasireotide 1nintedanib 1motesanib diphosphate 1mercaptoundecahydrododecaborate 1lenvatinib 1fluorodopa F 18 1cixutumumab 1anlotinib 1aldesleukin 1Vorinostat 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Medullary × anlotinib × Clear all
NCT02586350 2019-05-21

Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2/3 Completed
91 enrolled

Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡